142 related articles for article (PubMed ID: 3632912)
1. Teniposide is not effective in chronic lymphocytic leukemia.
Zagonel V; Tirelli U; Veronesi A; Galligioni E; Tumolo S; Roncadin M; Carbone A; Grigoletto E
Blut; 1986 Jan; 52(1):59-61. PubMed ID: 3632912
[TBL] [Abstract][Full Text] [Related]
2. The epipodophyllotoxin teniposide in therapy for childhood acute lymphocytic leukemia.
Rivera GK
J Clin Oncol; 1988 Feb; 6(2):191-3. PubMed ID: 3276820
[No Abstract] [Full Text] [Related]
3. VM26 in malignant hematological diseases. A phase II study.
Tirelli U; Carbone A; Franchin G; Galligioni E; Veronesi A; Trovo MG; Volpe R; Tumolo S; Grigoletto E
Cancer Chemother Pharmacol; 1982; 7(2-3):173-4. PubMed ID: 6952964
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of teniposide in advanced breast cancer.
Boas J; Rasmussen D; Hansen OP; Engelholm SA; Dombernowsky P
Cancer Chemother Pharmacol; 1990; 25(6):463-4. PubMed ID: 2311176
[TBL] [Abstract][Full Text] [Related]
5. Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma. A Southeastern Cancer Study Group trial.
Cox EB; Vogel CL; Carpenter JT; Raney M
Invest New Drugs; 1988 Apr; 6(1):37-9. PubMed ID: 3410666
[TBL] [Abstract][Full Text] [Related]
6. Severe hypertensive reactions to teniposide (VM-26) in infants with congenital leukemia.
Shimizu H; Frankel LS; Culbert SJ
Am J Pediatr Hematol Oncol; 1987; 9(3):239-41. PubMed ID: 3479027
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of teniposide (VM-26) in multiple myeloma.
Tirelli U; Carbone A; Zagonei V; Brema F; Veronesi A; Grigoletto E; Volpe R
Am J Clin Oncol; 1985 Aug; 8(4):329-31. PubMed ID: 3909805
[TBL] [Abstract][Full Text] [Related]
8. VM26 therapy in children with drug-refractory lymphocytic leukemia.
Rivera G; Dahl GV; Murphy SB; Bowman WP; Aur RJ; Avery TL; Simone JV
Cancer Chemother Pharmacol; 1982; 7(2-3):169-72. PubMed ID: 7083458
[No Abstract] [Full Text] [Related]
9. Phase II study of VM-26 in acute leukemia, neuroblastoma, and other refractory childhood malignancies: a report from the Children's Cancer Study Group.
Bleyer WA; Krivit W; Chard RL; Hammond D
Cancer Treat Rep; 1979 Jun; 63(6):977-81. PubMed ID: 380803
[TBL] [Abstract][Full Text] [Related]
10. Teniposide (VM-26) and ara-C in the treatment of adult acute lymphoblastic leukemia.
Linker CA; Levitt LJ; O'Donnell M; Ries CA; Forman SJ
Semin Oncol; 1987 Jun; 14(2 Suppl 1):78-85. PubMed ID: 3473686
[No Abstract] [Full Text] [Related]
11. High-dose teniposide for refractory malignancies: a phase I study.
de Vries EG; Mulder NH; Postmus PE; Vriesendorp R; Willemse PH; Sleijfer DT
Cancer Treat Rep; 1986 May; 70(5):595-8. PubMed ID: 3708608
[TBL] [Abstract][Full Text] [Related]
12. Allergic reactions to teniposide in patients with neuroblastoma and lymphoid malignancies.
Hayes FA; Abromowitch M; Green AA
Cancer Treat Rep; 1985 Apr; 69(4):439-41. PubMed ID: 3857970
[TBL] [Abstract][Full Text] [Related]
13. Phase I-II trial of VM-26 (NSC-122819) in the treatment of children with late-stage leukemia.
Rosenstock JG; Donaldson MH
Cancer Treat Rep; 1976 Mar; 60(3):265-7. PubMed ID: 1063066
[No Abstract] [Full Text] [Related]
14. Epipodophyllotoxin VM-26 in the treatment of childhood neuroblastoma.
Rivera G; Green A; Hayes A; Avery T; Pratt C
Cancer Treat Rep; 1977 Oct; 61(7):1243-8. PubMed ID: 589594
[TBL] [Abstract][Full Text] [Related]
15. Teniposide in the treatment of leukemia: a case study of conflicting priorities in the development of drugs for fatal diseases.
Grem JL; Hoth DF; Leyland-Jones B; King SA; Ungerleider RS; Wittes RE
J Clin Oncol; 1988 Feb; 6(2):351-79. PubMed ID: 3276827
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of VM-26 in patients with metastatic malignant melanoma.
Bellet RE; Catalno RB; Mastrangelo MJ; Berd D; Koons LS
Cancer Treat Rep; 1978 Mar; 62(3):445-7. PubMed ID: 348313
[No Abstract] [Full Text] [Related]
17. A phase II trial of teniposide (VM 26) in advanced non-Hodgkin's lymphoma, with emphasis on the treatment of elderly patients.
Tirelli U; Carbone A; Crivellari D; Volpe R; Franchin G; Veronesi A; Galligioni E; Trovò M; Tumolo S; Grigoletto E
Cancer; 1984 Aug; 54(3):393-6. PubMed ID: 6375853
[TBL] [Abstract][Full Text] [Related]
18. Teniposide in epithelial ovarian carcinoma: a phase II trial of the Gynecologic Oncology Group.
Muss H; Bundy BN; DiSaia PJ; Twiggs LB
Cancer Treat Rep; 1986 Oct; 70(10):1231-2. PubMed ID: 3530450
[No Abstract] [Full Text] [Related]
19. Teniposide in refractory ovarian cancer: a phase II study.
Sessa C; D'Incalci M; Landoni F; Colombo N; Mangioni C
Cancer Treat Rep; 1984 May; 68(5):815-6. PubMed ID: 6722838
[No Abstract] [Full Text] [Related]
20. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial.
Rodman JH; Abromowitch M; Sinkule JA; Hayes FA; Rivera GK; Evans WE
J Clin Oncol; 1987 Jul; 5(7):1007-14. PubMed ID: 3598607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
